Review of selected patents for cancer therapy targeting tumor angiogenesis

Mark N Kirstein, Megan M. Moore, Arkadiusz Z Dudek

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.

Original languageEnglish (US)
Pages (from-to)153-161
Number of pages9
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume1
Issue number2
DOIs
StatePublished - Dec 1 2006

Fingerprint

Patents
Neoplasms
Therapeutics
Biological Phenomena
Angiogenesis Inhibitors
Drug Delivery Systems
Clinical Trials
Technology
Research
Pharmaceutical Preparations

Keywords

  • Indolinones
  • Tumor angiogenesis
  • Vascular endothelial growth factor

Cite this

Review of selected patents for cancer therapy targeting tumor angiogenesis. / Kirstein, Mark N; Moore, Megan M.; Dudek, Arkadiusz Z.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 1, No. 2, 01.12.2006, p. 153-161.

Research output: Contribution to journalReview article

@article{cd4901fa14434ed393a4cbb00f82db98,
title = "Review of selected patents for cancer therapy targeting tumor angiogenesis",
abstract = "Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.",
keywords = "Indolinones, Tumor angiogenesis, Vascular endothelial growth factor",
author = "Kirstein, {Mark N} and Moore, {Megan M.} and Dudek, {Arkadiusz Z}",
year = "2006",
month = "12",
day = "1",
doi = "10.2174/157489206777442269",
language = "English (US)",
volume = "1",
pages = "153--161",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Review of selected patents for cancer therapy targeting tumor angiogenesis

AU - Kirstein, Mark N

AU - Moore, Megan M.

AU - Dudek, Arkadiusz Z

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.

AB - Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.

KW - Indolinones

KW - Tumor angiogenesis

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=39049113004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049113004&partnerID=8YFLogxK

U2 - 10.2174/157489206777442269

DO - 10.2174/157489206777442269

M3 - Review article

VL - 1

SP - 153

EP - 161

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 2

ER -